SCHEMBL1120119

SCHEMBL1120119

N#C/C(Cc1ccccc1)=C(/C#N)S(=O)(=O)Cc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MMP13 P45452 1/20 0.40
PRSS1 P07477 2/20 0.39
PRSS2 P07478 2/20 0.39
PRSS3 P35030 2/20 0.39
FAAH O00519 1/20 0.39
ELANE P08246 1/20 0.39
PRTN3 P24158 1/20 0.39
CA5A P35218 1/20 0.39
CA9 Q16790 1/20 0.39
MAPT P10636 1/20 0.37
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
AKR1B1 P15121 1/20 0.37
HSP90AA1 P07900 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1120121 1.00 CA1 (0.40) CA1CA2MMP1MMP2MMP9
SCHEMBL8967450 0.71 CES1 (0.43) CES2CES1AKR1B1KMT2ATSHR
SCHEMBL14194428 0.70 CES2 (0.41) CES2CES1AKR1B1KMT2AMEN1
SCHEMBL11131330 0.70 CYP1A1 (0.42) CES2CES1AKR1B1KMT2ATSHR
SCHEMBL4373160 0.69 MAPT (0.41) CA1CA2MMP1MMP2MMP9
SCHEMBL4373163 0.69 MAPT (0.41) CA1CA2MMP1MMP2MMP9
SCHEMBL3241398 0.67 PRSS1 (0.50) CA1CA2MMP1MMP2MMP9
SCHEMBL1457443 0.67 CA1 (0.54) CA1CA2MMP1MMP2MMP9
SCHEMBL8479057 0.66 PRSS1 (0.41) CA1CA2MMP1MMP2MMP9
SCHEMBL7594223 0.65 PRSS1 (0.52) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011130395-A1 INHIBITORS OF FLIP TO TREAT CANCER UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2011-10-20 WO disclosed
US-20110251135-A1 INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2011-10-13 US disclosed
US-7989495-B2 3-Sulfonyl propenenitriles, e.g., BAY 11-7085 (3-(t-butylphenylsulfonyl)-2-propenenitrile; promoting apoptosis and inhibiting readhesion of cancer cells; antimetastasis agents, particularly for hepatic, parietal or peritoneal area; inhibiting tumorigenesis; antiproliferative agents (not for myeloma) UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2011-08-02 US disclosed
EP-2281077-A2 INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS University of Utah Research Foundation (US) 2011-02-09 EP disclosed
US-20050124590-A1 Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124590-A1 Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells NFKBIA, RELA, NFKB1 CA1 1475/4885CA2 3319/4885MMP1 461/4885
US-20110251135-A1 INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS NFKBIA, IKBKB, RELA CA1 872/4885CA2 2897/4885MMP1 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.